TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03371017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
Study: NCT03995108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavorixafor
Description: Mavorixafor provided as 100 mg capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mavorixafor
Description: Mavorixafor provided as 100 mg capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to mavorixafor capsules
Study: NCT03337607

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rESWT
Description: rESWT will be performed as follows:~* Four rESWT sessions~* One rESWT session per week~* 4 × 1000 radial extracorporeal shock waves (rESWs) per session (1000 rESWs each applied to the left and the right paravertebral muscles above L3 to S1 using the 36-mm applicator, plus 1000 rESWs each applied to the left and the right sacroiliac joint using the 15-mm convex applicator, in prone position of the patient.~* rESWs applied at 15 Hz~* Air pressure of the rESWT device gradually increased during the first 200 rESWs each until the maximum discomfort the patient can tolerate will be reached, followed by 800 rESWs at this air pressure / energy flux density.~* No application of local anaesthetics

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rESWT
Description: rESWT will be performed as follows:~* Four rESWT sessions~* One rESWT session per week~* 4 × 1000 radial extracorporeal shock waves (rESWs) per session (1000 rESWs each applied to the left and the right paravertebral muscles above L3 to S1 using the 36-mm applicator, plus 1000 rESWs each applied to the left and the right sacroiliac joint using the 15-mm convex applicator, in prone position of the patient.~* rESWs applied at 15 Hz~* Air pressure of the rESWT device gradually increased during the first 200 rESWs each until the maximum discomfort the patient can tolerate will be reached, followed by 800 rESWs at this air pressure / energy flux density.~* No application of local anaesthetics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 1 x 200 mg per day for moderate pain (Numerical Rating Scale score 4-6 on an 11-point scale where 0 indicates no pain and 10 indicates worst imaginable pain), or 2 x 200 mg per day (Numerical Rating Scale 7-10), respectively, for four weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 1 x 200 mg per day for moderate pain (Numerical Rating Scale score 4-6 on an 11-point scale where 0 indicates no pain and 10 indicates worst imaginable pain), or 2 x 200 mg per day (Numerical Rating Scale 7-10), respectively, for four weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eperisone
Description: 3 x 50 mg per day for four weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eperisone
Description: 3 x 50 mg per day for four weeks
Study: NCT03371017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle
Study: NCT05440370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MegaCarti®
Description: MegaCarti® application after microfracture through athroscopic or incision surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture
Description: Microfracture through athroscopic or incision surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Microfracture through athroscopic or incision surgery
Study: NCT01220700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triclosane
Description: Triclosane coated suture material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Ordinary suture material
Study: NCT01786902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-3002
Study: NCT01091948

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation with Fiberoptic laryngoscope
Description: Subjects will be intubated with the Fiberoptic laryngoscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GlideScope® Video Laryngoscope
Description: Patients will be intubated with the GlideScope® Video Laryngoscope.
Study: NCT04371146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 35 mg methylphenidate (Ritalin®) is administered once using a randomized placebo-controlled between subject's design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reboxetine
Description: 8 mg Reboxetine (Edronax®) is administered once using a randomized placebo-controlled between subject's design

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: A placebo pill is administered once using a randomized placebo-controlled between subject's design
Study: NCT02161302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA current.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
Study: NCT02536365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Integration Therapy
Description: Children in the SIT treatment group will receive a manualized SIT intervention that follows the principles of sensory integration.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applied Behavioral Analysis
Description: Children in the ABA treatment group will receive intervention that follows the principles of Applied Behavioral Analysis.
Study: NCT04162093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uretero ileal anastomosis in single trough
Study: NCT02493296

Intervention type: OTHER
Intervention: This observational study will not entail an intervention.
Description: This study will entail measurement of central aortic haemodynamics before and after (clinically indicated) abdominal aortic aneurysm repair
Study: NCT01795365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active surveillance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active surveillance
Study: NCT03017079

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: semi-solid agent with standard enteral feeding
Description: after infusion of semi-solid agent, Intermittent enteral feeding is applied less than 60 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard enteral feeding
Description: Intermittent enteral feeding is applied less than 60 minutes
Study: NCT03403348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
Study: NCT02804347

Intervention type: DEVICE
Intervention: Cognitive Function Imaging and Battery
Description: Individuals will be placed in the fMRI scanner and complete the NBACK Cognitive Task
Study: NCT03371017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
Study: NCT02804347

Intervention type: DEVICE
Intervention: Cognitive Function Imaging and Battery
Description: Individuals will be placed in the fMRI scanner and complete the NBACK Cognitive Task

Intervention type: DEVICE
Intervention: Sniffin Sticks
Description: Using Sniffin Sticks, olfactory functioning will be assessed using three tests: identification, discrimination, and threshold.
Study: NCT03403348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
Study: NCT02296554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLAP Repair
Description: SLAP repair for SLAP tear

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biceps Tenodesis
Description: Biceps tenodesis for SLAP tear
Study: NCT01637103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive therapy of depression
Description: Cognitive therapy will involve eight individual weekly sessions of 50 minutes with a Ph.D. student in psychology.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Description: Bright light therapy will consist of a 30-min daily morning exposition to a 10 000-lux BLT lamp during 8 weeks.
Study: NCT02021175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored CBME Therapy via Technology
Description: 6 Sessions of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Referral to currently available resources for 6 sessions of a standard smoking cessation approach
Study: NCT03204955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride /sodium acetate (16.4%)
Description: Sodium Acetate is a sterile, nonpyrogenic solution of Sodium Acetate intended as an alternative to sodium chloride to provide sodium ion in parenteral (IV) fluid therapy.~Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride (23.4%)
Description: Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PlasmaLyte
Description: PlasmaLyte is an isotonic IV solution that mimics human physiological plasma electrolyte concentrations, osmolality and pH.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PlasmaLyte
Description: PlasmaLyte is an isotonic IV solution that mimics human physiological plasma electrolyte concentrations, osmolality and pH.
Study: NCT04747730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation training
Description: The programme targets inmates in HMP Warren Hill who are eligible to learn the meditation technique, who are staying in prison for at least six months since the beginning of the programme and who provide the signed informed consent. The sample of eligible inmates is approximately 190 inmates out of 250 currently in the prison. Inmates will be contacted by the research team in prison during introductory sessions of the research intervention.
Study: NCT01714804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accell Evo3 Prospective Use
Study: NCT01210430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Subjects will receive placebo or losartan for 4 weeks. Days 1-7, subjects will receive 12.5mg of Losartan or placebo. Days 7-14, subjects will receive 25mg of Losartan or placebo. Days 14-28, subjects will receive 50mg of Losartan or placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid (Vitamin C)
Description: Subjects will receive 60mg/kg of Ascorbic Acid over 20 minutes followed by a maintenance infusion of 20mg/kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Subjects will receive 60mg/kg of normal saline over 20 minutes followed by a maintenance infusion of 20mg/kg of normal saline.
Study: NCT00490256

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Selective Cerebral Perfusion
Description: Modified Selective perfusion is a cardiopulmonary bypass circuit that has been modified to allow blood flow to the lower body as well as the upper body while the surgery is being performed.
Study: NCT02168530

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo administered daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: vismodegib 150 mg administered daily orally
Study: NCT02592538

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: radiofrequency ablation
Description: All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: In the RFA plus S-1 group, treatment with S-1 began within 1 month after RFA. Based on the patient's body surface area, S-1 was administered as follows: when the level of total bilirubin was less than 2 mg/dl. Based on the body surface area, S-1 was administered if \<1.25 m2, 80 mg/day; if 1.25-1.5 m2, 100 mg/day; if≥1.5 m2, 120 mg/day. S-1 was administered orally twice daily for 14 days, followed by 7 days without treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Stent
Description: Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent
Description: Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
Study: NCT00929825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical stimulation (Elastomers)
Description: The instrument of mastication, sialogogue should be used 4 times a day for 10 minutes each time always after meals

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical stimulation (Elastomers)
Description: The instrument of mastication, sialogogue should be used 4 times a day for 10 minutes each time always after meals

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS
Description: transcutaneous electrical stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS
Description: transcutaneous electrical stimulation
Study: NCT02804347

Intervention type: DEVICE
Intervention: Sniffin Sticks
Description: Using Sniffin Sticks, olfactory functioning will be assessed using three tests: identification, discrimination, and threshold.

Intervention type: OTHER
Intervention: Cognitive Batteries
Description: Participants will conduct the following cognitive batteries: DSST, TMT A \& B, RAVLT

Intervention type: OTHER
Intervention: Cognitive Batteries
Description: Participants will conduct the following cognitive batteries: DSST, TMT A \& B, RAVLT
Study: NCT01177228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab for intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion
Study: NCT01083537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 1) Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~1. Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~2. Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 2) Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~1. Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~2. Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~3. Hydration: Infuse Paclitaxel in 250cc NS over 1 hour
Study: NCT00472069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplantation of the squeletic muscular cells
Description: transplantation of the squeletic muscular cells
Study: NCT01355601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Beverage
Description: Nutritional Beverage with varying types and levels of carbohydrates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Beverage
Description: Nutritional beverage with varying types and levels of carbohydrates
Study: NCT00779779

Intervention type: BIOLOGICAL
Intervention: Rotarix™
Description: Two oral doses, with at least 4 weeks interval in-between
Study: NCT03953339

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Release or no release of the suprascapular nerve
Study: NCT04106336

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Repetitive transcranial magnetic stimulation (rTMS) will be done for cannabis addict
Study: NCT02822040

Intervention type: OTHER
Intervention: Intraoral Scan
Description: All patients will have an intraoral scan performed for measurements to be taken on.
Study: NCT03953339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Release or no release of the suprascapular nerve
Study: NCT01146314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Focused Lifestyle Intervention
Description: The lifestyle intervention is a 6-month intervention study lasting 6 months. The intervention is 14 sessions and conducted by a dietician and psychologist in a group setting with each intervention session lasting 90 minutes. The sessions are conducted weekly, biweekly, and monthly over the course of 6 months.
Study: NCT04392063

Intervention type: DRUG
Group type: OTHER
Intervention: Melatonin 3 mg
Description: The children received crushed Melatonin 3-mg tablets daily, 30-minutes before bedtime for 3-months.
Study: NCT02817035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive mechanical ventilation
Description: To examined the physiological signals of patients and healthy subjects during spontaneous breathing and noninvasive mechanical ventilation.